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Trelagliptin (TLN) is a novel once-weekly antidiabetic drug that enhanced the patient compliance in type 2 diabetes. TLN analysis
and bioanalysis literature review showed many methods for TLN assay either in dosage form or as biological ﬂuids (pharmacokinetic parameters), but all those methods did not consider the full details dealing with biological assay of TLN. Studies that
included information about pharmacokinetic parameters did not mention the used analytical procedures for those determinations
and parameters. Although some LC-MS/MS and UPLC-UV methods were reported for TLN bioassay in rats’ plasma, they used
direct precipitation techniques, and the current described procedure showed lower LLOQ than all the reported methods in spite of
that working on human plasma is more complicated than on rats’ plasma. In this study, LC-MS/MS bioanalysis of TLN in human
plasma (4–1000 nM) was employed successfully with LLOQ of 4 nM which is lower than all reported methods in rats’ plasma
followed by a preliminary pharmacokinetic study. Alogliptin was used as internal standard (IS) because of its structure similarity
to TLN. Pharmacokinetic parameters of TLN were investigated in Egyptian volunteers, and they had been compared to Japanese.
Liquid-liquid extraction showed more sensitive results than direct precipitation. The proposed method was successfully applied to
a pharmacokinetic study conducted on Egyptian volunteers. No dose modiﬁcation is required upon comparing the pharmacokinetic parameters of the current study and previous studies on non-Egyptian volunteers.

1. Introduction
Trelagliptin (TLN, Figure 1) inhibits dipeptidyl peptidase-4
enzyme increasing GLP-1 to treat type 2 diabetes. In addition to its insulin secretagogue eﬀect, it also improves
insulin resistance [1]. It had been approved for use in Japan
in March 2015 by Takeda pharmaceutical Company as
Zafatek® tablets. As a once-weekly drug, it enhances the
patient adherence to the treatment regimen instead of the
other previously approved gliptins. TLN showed high safety
proﬁle with patients suﬀering from end-stage renal disease

or even with renal impairment [2]. Moreover, TLN was
repositioned as a potential therapeutic agent for metabolic
syndrome with polypharmacologic eﬀects that will lower the
treatment cost as one drug with multifaceted therapy [3].
Also, repositioning of TLN and its sister gliptins for neurodegenerative diseases is suggested based on improving
insulin resistance in the brain [4]. TLN is a well-tolerated
drug with less dosing frequency and less-serious adverse
events [5]. TLN clinical trials have conﬁrmed that it can
eﬀectively control the plasma concentration of glucose and
HbA1c in type 2 diabetic patients [6].
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Figure 1: MS of TLN and its chemical structure.

TLN analysis and bioanalysis literature review showed
many methods [7–13] for TLN assay either in dosage form or
as biological ﬂuids (pharmacokinetic parameters). An LC
method for determination of enantiomeric purity of TLN
was reported [7]. Some other stability-indicating LC
methods were developed for TLN assay in the presence of
impurities and/or degradation products [8–11], but all those
methods were not related to biological assay of TLN. Studies
that included information about pharmacokinetic parameters [5, 12, 13] did not mention the used analytical procedures for those determinations and parameters. Although
some LC-MS/MS and UPLC-UV methods were used for
TLN bioassay in rats’ plasma [14–18], they used direct
precipitation techniques, and the current described procedure showed lower LLOQ than all the reported methods in
spite of that working on human plasma is more complicated
than on rats’ plasma. The use of two extracting solvents’
mixture (TBME and DEE) besides the upgrading of the
detector, to be mass spectrometry instead of photodiode
array [15], has greatly encouraged the authors to go further
within this preliminary pharmacokinetic study.
In this study, LC-MS/MS bioanalysis of TLN in human
plasma (4–1000 nM) was employed successfully with LLOQ
of 4 nM which is lower than all reported methods in rats’
plasma followed by a preliminary pharmacokinetic study.
Pharmacokinetic parameters of TLN were investigated in
Egyptian volunteers, and they had been compared to Japanese race results obtained from the literature. Extraction of
TLN from plasma enhanced using liquid-liquid extraction
followed by vacuum evaporation that showed more sensitive
results than direct precipitation.

2. Methods
2.1. Chemicals and Chromatographic Conditions. TLN
(99.0%), Alogliptin as IS (99.2%), ZAFATEK (50 mg) tablets,
TBME, and DEE were thankfully contributed by the Center for
Drug Research and Development, at the British University in
Egypt, BUE (Cairo, Egypt). HPLC-grade methanol and acetonitrile were purchased from (Sigma, USA). The Phenomenex
C18 column (1.6 μm, 150 × 2.1 mm), Waters UPLC-TQ, and
Mass Lynx software, with a ﬂow rate of 0.3 mL/min, mixture of
acetonitrile/0.3 formic acid (90 :10, v/v) as an isocratic mobile
phase, and injection V of 10 μL, were used. Cone voltage values
of 25 V and 30 V and collision energy values of 60 eV and 55 eV
were applied for TLN and IS (Alogliptin), respectively. MRM of
m/z 358.2 to 133.9 for TLN and m/z 340.2 to 116.0 for IS in the
ESI positive mode were applied.

®

®

2.2. Calibrators, QC Samples, and Sample Preparation.
10 μL from each of the TLN working solutions (0.4, 1.2, 2.5,
10, 40, 50, 70, 80, and 100 μM) had been added to 990 μL
blank plasma, so the ﬁnal concentrations were 4 nM (LLOQ),
12 nM (LQC) 25, 100, 400, and 500 nM (MQC), and 700 and
800 (HQC) and 1000 nM. For the sample preparation, 100 μL
of IS (300 nM, solvent as acetonitrile) was added to 250 μL of
each sample, and then, 1.5 mL of (TBME and DEE mixture,
50 : 50, v/v) was added followed by 15 minutes centrifugation
at 15.000 rpm. Withdrawal of clear 1.3 mL from the upper
layer was successful, and it was subjected to vacuum and
evaporated till dryness and reconstituted with 250 μL
methanol before the chromatographic run.
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Figure 2: MS of IS and its chemical structure.

2.3. Bioanalytical Validation and Biological Samples. As per
FDA bioanalytical validation guidance [19], six diﬀerent
concentrations had been used for the calibration curve estimation and six batches from diﬀerent plasma sources were
checked for selectivity. Both accuracy and precision parameters (n � 5) had been evaluated using the calibration
parameters (bias, S.D., % RSD) based on bioanalysis of
LLOQ, LQC, MQC, and HQC levels. Carry over, matrix
factor, and extraction recoveries were evaluated as per FDA
bioanalytical validation guidance [19]. Four types of stability
were checked for LQC and HQC samples that included
leaving the samples for three hours either at room temperature or in the auto sampler, 3 cycles freeze and thaw
stability, and 2 weeks (−80 °C) stability.
The pharmacokinetic parameters of TLN were studied in
healthy human subjects according to the relevant ethical
guidelines and regulations of the World Medical Association
Declaration of Helsinki (October 1996) and the International Conference of Harmonization Tripartite Guideline for
Good Clinical Practice. Each volunteer before enrollment
provided written informed consent. Approval of the study
by the ethical committee was mandatory according to the
Egyptian Ministry of Health and the British University in
Egypt research ethics guidelines. The randomized clinical
trial experimental protocol was ﬁnally approved by the
British University in Egypt (BUE) Faculty of Pharmacy
ethical committee, Code : CL/2004, on 05/08/2020 after
preliminary discussion and proposal submission in April
2020. The mentioned BUE ethical committee is recognized
by the ENREC (Egyptian Network of Research Ethics
Committees), http://www.enrec.org/directory. The clinical

trial protocol was previously registered in a publically accessible primary register that participates in the WHO International
Clinical
Trial
Registry
Platform
(ClinicalTrials.gov, registration date: 05/05/2020, ID:
NCT04374864), and it is available online at (https://
clinicaltrials.gov/ct2/show/NCT04374864). 1 mL blood
samples from six human volunteers (25–39 years) was collected at 0, 0.5, 1, 1.5, 2, 2.5, 3, 8, 24, 48, 72, 96, 120, 144, and
168 hrs after oral administration of 50 mg TLN as Zafatek®
tablet. The samples were collected in EDTA tubes and
centrifuged for 5 min (3000 rpm) then the plasma samples
were treated as under sample preparation to calculate the
determinations. Cmax, Tmax, t1/2 (0-96), elimination rate
constant, AUC0-t (0-96), and AUC0-inf were estimated using a
validated excel sheet.

3. Results and Discussion
Trelagliptin (TLN) is a novel once-weekly antidiabetic drug
that enhanced the patient compliance in type 2 diabetes
[20–24]. TLN analysis and bioanalysis literature review
showed many methods for TLN assay either in dosage form
or as biological ﬂuids (pharmacokinetic parameters), but all
those methods did not consider the full details dealing with
biological assay of TLN. Studies that included information
about pharmacokinetic parameters did not mention the used
analytical procedures for those determinations and parameters. Based on previous experience of the authors with
the handling of TLN plasma samples either dealing with rats’
plasma or human plasma [15], one of the main targets in this
study is to enhance TLN extraction that was achieved by
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Figure 3: TLN daughter ions (+ESI) at m/z � 133.94.
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Figure 4: IS daughter ions (+ESI) at m/z � 116.02.

liquid-liquid extraction using a mixture of two organic
solvents (TBME and DEE). In comparison with previous
work where only diethyl ether was used as the extracting

solvent for TLN and IS, higher sensitivity was achieved in
this presented study where a mixture of two organic solvents
was used in addition to acetonitrile added to extract the IS.
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Figure 5: Blank plasma sample (for testing selectivity) showing no interference from endogenous plasma components either with TLN or
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Figure 6: Zero human plasma sample showing IS only.

The use of two extracting solvents’ mixture (TBME and
DEE) besides the upgrading of the detector, to be mass
spectrometry instead of photodiode array, has greatly encouraged the authors to go further into this preliminary
pharmacokinetic study.
Bioassay
(LC-MS/MS)
of
TLN
(4–1000 nM,
y � 0.0036x + 0.0099, r � 0.9994) was employed. Positive ESI
Multiple Reaction Monitoring of m/z 358.2 to 133.9 for TLN
and m/z 340.2 to 116.0 for IS was adopted, as depicted in
Figures 1–4. Satisfactory results for selectivity from blank
plasma samples without interference, zero sample, and
LLOQ sample of 4 nM are shown in Figures 5–7, and all QC
samples (Figure 8) are presented. Accuracy and precision
showed satisfactory results of ±20% (Table 1). Extraction
recovery ranged from 82.92% to 83.85%. Matrix factor
ranged from 87.23% to 97.17%. All stability determinations

0
0.50
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1.00

0.50
min

1.00

Figure 7: LLOQ sample (4 nMol/L of TLN) using MRM, (m/z � 358.2
to 133.9) and (IS, m/z � 340.2 to 116.0).

showed recoveries more than 85% (ranged from 89.33% to
96.87%). No carry over was observed after injection of blank
after the HQC samples. Dilution integrity samples showed a
recovery of 96.9% after dilution 5-folds.
Successful application of the developed method to a
pharmacokinetic study conducted on Egyptian volunteers
was employed (Figure 9). Plotting of the mean human
plasma concentrations against time is shown in Figure 10.
Regarding ethnic diﬀerence, the Egyptian pharmacokinetic
parameters were compared to Japanese, as previously reported [5, 12, 13]. The calculated pharmacokinetic parameters in the current work were closely related to previous
studies conducted in Japanese subjects using 50 mg TLN.
The values of Cmax, Tmax, and AUC0-∞ (Table 2) were similar
to those data obtained from Japanese [5, 12, 13], while t1/2
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Figure 8: MRM of TLN (m/z � 358.2 to 133.9) and (IS, m/z � 340.2 to 116.0) in LQC, 12 ng/mL (a), MQC, 500 ng/mL (b), and 800 ng/mL
HQC (c) spiked human plasma validation samples.

showed some deviation than some studies, but it was close to
one study that considered hepatic and nonhepatic impaired
patients as 22.6 ± 9.14 [12]. This insigniﬁcant diﬀerence
recommends that no dose adjustment is required in the
administration of 50 mg TLN by the Egyptian population.

The conducted study was capable of calculating the main
parameters although it was not possible to quantify TLN in
samples collected between 120 and 168 h due to their low
concentrations below the LLOQ of the developed method
(4 nM).
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Table 1: Accuracy and precision results for TLN bioassay.
Accuracy and precision (n � 5, three days)
Average recovery
Bias (mean, n � 5)
1st day, intraday
S.D.
% R.S.D
Average recovery
Bias (mean, n � 5)
2nd day, intraday
S.D.
% R.S.D
Average recovery
Bias (mean, n � 5)
3rd day, intraday
S.D.
% R.S.D
Average recovery
Bias (mean, n � 5)
Interday
S.D.
% R.S.D

LLOQ (4 nMol/L)
80.0
−20.0
13.71
17.14
80.76
−19.24
11.09
13.74
81.32
−18.68
9.80
12.05
80.56
−19.44
12.38
15.36

Trelagliptin
T

100

100

%

LQC (12 nMol/L)
109.89
9.89
7.65
6.96
103.61
3.61
3.85
3.72
102.79
2.79
5.57
5.42
105.56
5.56
6.96
6.59

MQC (500 nMol/L)
92.85
−7.15
4.58
4.92
99.80
−0.20
2.16
2.16
97.74
−2.26
2.17
2.22
96.80
−3.20
4.31
4.45
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HQC (800 nMol/L)
96.28
−3.72
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4.21
99.40
−0.60
1.03
1.04
97.20
−2.80
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97.63
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Figure 9: MRM of TLN (m/z � 358.2 to 133.9) and (IS, m/z � 340.2 to 116.0) in the human volunteer plasma sample obtained after (a) 5 days
(close to Cmin) and (b) after 1 hr (close to Cmax) of TLN (50 mg).
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Figure 10: The plasma concentrations versus time curve of TLN after administration of Zafatek tablet (50 mg TLN).
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Table 2: Pharmacokinetic parameters of 50 mg TLN after administration to healthy Egyptian volunteers (n � 6).

Pharmacokinetic parameters
Cmax (nMol/L) as mean ± S.D. Cmax (highest value–lowest value)
Cmax (ng/mL) as mean ± S.D. Cmax (highest value–lowest value)
Tmax (hours) as mean ± S.D. Tmax (highest value–lowest value)
Elimination rate constant (h−1) as mean ± S.D. (highest value–lowest value)
t1/2 (0-96) (hours) as mean ± S.D. (highest value–lowest value)
AUC 0-t (nMol∗ h/L) as mean ± S.D. (t � 96)
AUC 0-inf (nMol∗ h/L) as mean ± S.D.
AUC 0-t (ng∗ h/mL) as mean ± S.D. (t � 96)
AUC 0-inf (ng∗ h/mL) as mean ± S.D.

Trelagliptin
629.23 ± 57.04 (695.47–560.63)
225.37 ± 20.43 (249.09–200.80)
1.1 ± 0.34 (1.5–0.5)
0.046353 ± 0.004213 (0.0498422 and 0.0375328)
15.1 ± 1.6 (18.5 and 14.0)
9827.2 ± 1075.8
9982.5 ± 1027.4
3519.8 ± 385.3
3575.4 ± 368.0

4. Conclusions
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method for TLN using a mixture of two organic solvents was
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with successful application to a pharmacokinetic study
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required upon comparing the pharmacokinetic parameters
of the current study and previous studies conducted on nonEgyptian volunteers.
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